UnitedHealthcare spurns Gilead’s newer PrEP drug Descovy as Truvada generic looms: report
UnitedHealthcare has a history of limiting HIV drug costs, including offering cash incentives to patients who opt for low-priced regimens. Now, in a potentially major blow to HIV giant Gilead Sciences, the insurer has set its eyes on one of the California drugmaker’s new therapies. Gilead’s new HIV PrEP option, Descovy, will no longer be covered… Read More »